Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $891.0 million.

  • Ani Pharmaceuticals' Total Non-Current Liabilities rose 652.22% to $891.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $891.0 million, marking a year-over-year increase of 652.22%. This contributed to the annual value of $835.3 million for FY2024, which is 9756.3% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Total Non-Current Liabilities is $891.0 million, which was up 652.22% from $863.3 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Total Non-Current Liabilities peaked at $891.0 million during Q3 2025, and registered a low of $251.8 million during Q1 2021.
  • For the 5-year period, Ani Pharmaceuticals' Total Non-Current Liabilities averaged around $498.6 million, with its median value being $412.8 million (2023).
  • Per our database at Business Quant, Ani Pharmaceuticals' Total Non-Current Liabilities plummeted by 586.91% in 2021 and then soared by 10159.23% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $381.9 million in 2021, then increased by 1.21% to $386.5 million in 2022, then increased by 9.4% to $422.8 million in 2023, then surged by 97.56% to $835.3 million in 2024, then grew by 6.66% to $891.0 million in 2025.
  • Its last three reported values are $891.0 million in Q3 2025, $863.3 million for Q2 2025, and $831.5 million during Q1 2025.